Standard Biotools (LAB) Revenue (2010 - 2026)

Standard Biotools (LAB) has reported Revenue for 17 consecutive years, with $20.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue fell 7.62% year-over-year to $20.1 million in Q2 2026; TTM through Jun 2026 was $84.6 million, a 4.78% decrease from a year earlier, with the FY2025 full-year figure at $85.3 million, down 6.24% from the prior year.
• Revenue was $20.1 million for Q2 2026 at Standard Biotools, down from $21.1 million in the prior quarter.
• Over five years, Revenue peaked at $45.5 million in Q1 2024 and troughed at $18.8 million in Q2 2022.
• A 5-year average of $24.8 million and a median of $24.3 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 72.22% in 2022 and surged 81.3% in 2024, its largest moves.
• Over 5 years, Revenue stood at $27.0 million in 2022, then rose by 4.32% to $28.2 million in 2023, then fell by 12.1% to $24.8 million in 2024, then slipped by 3.96% to $23.8 million in 2025, then fell by 15.51% to $20.1 million in 2026.
• The last three Revenue figures came in at $20.1 million (Q2 2026), $21.1 million (Q1 2026), and $23.8 million (Q4 2025), per Business Quant data.